Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.48 |
| ▸ | PRKCA | P17252 | 3/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.46 |
| ▸ | PRKCB | P05771 | 2/20 | 0.46 |
| ▸ | PRKCH | P24723 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 12/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771141 | 0.88 | GBA1 (0.43) | ROCK2ROCK1PKN2HTR6CYP1A2 | |
| SCHEMBL4774328 | 0.87 | GBA1 (0.43) | ROCK2ROCK1PKN2PRKD1HTR6 | |
| Hydrochloric Acid SCHEMBL4770876 | 0.87 | GBA1 (0.43) | ROCK2ROCK1PKN2HTR6CYP1A2 | |
| SCHEMBL4766761 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1PKN2PRKD1PRKCA | |
| SCHEMBL4774464 | 0.85 | ROCK2 (0.58) | ROCK2ROCK1PKN2PRKD1PRKCA | |
| SCHEMBL4767462 | 0.84 | DRD2 (0.47) | HTR6GBA1HTR1AHTR2ADRD2 | |
| Oxalic Acid SCHEMBL4772211 | 0.81 | KDM4E (0.46) | HTR6GBA1HTR1AHTR2ADRD2 | |
| SCHEMBL4772217 | 0.81 | HTR7 (0.42) | HTR6GBA1HTR1AHTR2ADRD2 | |
| SCHEMBL4765144 | 0.80 | HTR7 (0.46) | HTR6GBA1HTR1AHTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL4773769 | 0.79 | HTR7 (0.45) | HTR6GBA1HTR1AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | ROCK2 3313/4885ROCK1 2976/4885PKN2 1204/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | ROCK2 1825/4885ROCK1 1087/4885PKN2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.